Autophagy, metabolism, and cancer
Macroautophagy (autophagy hereafter) captures intracellular proteins and organelles and
degrades them in lysosomes. The degradation breakdown products are released from …
degrades them in lysosomes. The degradation breakdown products are released from …
Biomarkers for immunotherapy: current developments and challenges
Immunotherapy has revolutionized cancer therapy and has been named the cancer
advance of the year for 2016. Checkpoint inhibitors have demonstrated unprecedented rates …
advance of the year for 2016. Checkpoint inhibitors have demonstrated unprecedented rates …
Mucosal melanoma: epidemiology, biology and treatment
KR Spencer, JM Mehnert - Melanoma, 2016 - Springer
Mucosal melanoma is an exceedingly rare variant of cutaneous melanoma that, due to its
rarity, is poorly described and infrequently studied. Primary sites of origin include the head …
rarity, is poorly described and infrequently studied. Primary sites of origin include the head …
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab …
PURPOSE Biomarkers that can predict response to anti–programmed cell death 1 (PD-1)
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …
therapy across multiple tumor types include a T-cell–inflamed gene-expression profile …
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
Importance Ipilimumab and other immune therapies are effective treatment options for
patients with advanced melanoma but cause frequent immune-related toxic effects …
patients with advanced melanoma but cause frequent immune-related toxic effects …
Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study
PA Ott, YJ Bang, D Berton-Rigaud, E Elez… - Journal of Clinical …, 2017 - ascopubs.org
Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to
evaluate the safety and efficacy of pembrolizumab, an anti–programmed death 1 …
evaluate the safety and efficacy of pembrolizumab, an anti–programmed death 1 …
[PDF][PDF] Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study
PA Ott, E Elez, S Hiret, DW Kim, A Morosky… - J clin …, 2017 - clf1.medpagetoday.com
Purpose The safety and efficacy of pembrolizumab, a humanized monoclonal antibody
against programmed death 1 (PD-1), were assessed in patients with programmed death …
against programmed death 1 (PD-1), were assessed in patients with programmed death …
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study
Purpose To establish the safety profile and antitumor activity of the anti–programmed death
1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic …
1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic …
[HTML][HTML] Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
JM Mehnert, A Panda, H Zhong… - The Journal of …, 2016 - Am Soc Clin Investig
Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-
1) have resulted in prolonged and beneficial responses toward a variety of human cancers …
1) have resulted in prolonged and beneficial responses toward a variety of human cancers …
[HTML][HTML] Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 …
HC Chung, SA Piha-Paul, J Lopez-Martin… - Journal of Thoracic …, 2020 - Elsevier
Introduction Pembrolizumab has shown clinical benefit in patients with previously treated
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 …
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 …